Optimising management of chronic heart failure (Q43239376)

17 November 2017

Optimising management of chronic heart failure (English)

1 reference

17 November 2017

chronic heart failure

1 reference

1

Henry Krum

1 reference

PubMed ID

19922996

17 November 2017

language of work or name

English

0 references

publication date

16 November 2009

1 reference

17 November 2017

1 reference

17 November 2017

374

1 reference

17 November 2017

9704

1 reference

17 November 2017

1808-1809

1 reference

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

17 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961992-9

7 January 2021

10.1016/S0140-6736(09)61992-9

Identifiers

DOI

1 reference

17 November 2017

1 reference

PubMed ID

19922996